Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience

Omar Alhalabi, Elshad Hasanov, Nathaniel R. Wilson, John Araujo, Jianbo Wang, Matthew T. Campbell, Sangeeta Goswami, Amishi Y. Shah, Jianjun Gao, Pavlos Msaouel, Nizar M. Tannir

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience'. Together they form a unique fingerprint.

Medicine & Life Sciences